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ABSTRACT: Angiotensin II is a growth factor that plays a key role in the physiopathology of
idiopathic pulmonary fibrosis (IPF). A nucleotide substitution of an adenine instead of a guanine
(G-6A) in the proximal promoter region of angiotensinogen (AGT), the precursor of angiotensin II,
has been associated with an increased gene transcription rate.
In order to investigate whether the G-6A polymorphism of the AGT gene is associated with IPF
development, severity and progression, the present study utilised a case–control study design
and genotyped G-6A in 219 patients with IPF and 224 control subjects.
The distribution of G-6A genotypes and alleles did not significantly differ between cases and
controls. The G-6A polymorphism of the AGT gene was not associated with disease severity at
diagnosis. The presence of the A allele was strongly associated with increased alveolar arterial
oxygen tension difference during follow-up, after controlling for the confounding factors. Higher
alveolar arterial oxygen tension changes over time were observed in patients with the AA genotype
(0.37¡0.7 mmHg (0.049¡0.093 kPa) per month) compared to GA genotype (0.12¡1 mmHg
(0.016¡0.133 kPa) per month) and GG genotype (0.2¡0.6 mmHg (0.027¡0.080 kPa) per month).
G-6A polymorphism of the angiotensinogen gene is associated with idiopathic pulmonary
fibrosis progression but not with disease predisposition. This polymorphism could have a
predictive significance in idiopathic pulmonary fibrosis patients.
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I
diopathic pulmonary fibrosis (IPF) is a
specific form of chronic interstitial lung
disease, characterised histopathologically by
usual interstitial pneumonia and associated with
a poor prognosis [1]. IPF involves the loss of lung
architecture through increased epithelial cell
apoptosis and abnormal wound healing, fol-
lowed by fibroblast foci formation and excessive
lung collagen deposition. The triggering event is
thought to be multiple microscopic sites of
alveolar-capillary barrier injury, in which the
disruption of microvascular endothelium and the
apoptosis and activation of alveolar epithelium
induce the secretion of profibrotic molecules,
which in turn lead to the continuous fibrotic
response and the progression of the disease [2, 3].
The initial cause of IPF remains unknown;
however, it probably involves an interaction
between environmental and genetic factors.
Although the basis of individual susceptibility
to lung fibrosis is unclear, familial clustering of
IPF has been described, even in individuals
raised in different environments [4, 5]. Similar
genetic mutations in affected family members
have also been observed [6, 7], as well as in gene
expression profiling of sporadic IPF [8, 9]. These
observations, together with the failure of fibro-
genic agents, such as asbestos, amiodarone or
bleomycin, to trigger lung fibrosis in all exposed
individuals [1] suggest that genetic factors play
an important role in the development of pul-
monary fibrosis. Among the large number of
genes that could be involved in IPF susceptibility
or progression, the most attractive targets may
include the genes of mediators that influence the
process of alveolar epithelial cell activation and
lung wound healing [8–10].
Angiotensin (ANG) II is an essential mediator in
the pathogenesis of pulmonary fibrosis. It has
been shown that ANG II induces alveolar
epithelial cell apoptosis, enhances fibroblast
proliferation and lung collagen production, and
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increases transforming growth factor (TGF)-b1 synthesis [11–
13]. Angiotensinogen (AGT) is the precursor of ANG II. There
is a significant increase of AGT expression in the lungs of IPF
patients compared with normal lungs [14]. Furthermore, AGT
has been found to be one of the most overexpressed genes in
IPF lungs compared to the gene expression profile of other
interstitial lung diseases [8]. A modest increase in basal
expression of AGT may lead to a chronic rise in baseline
ANG II production. Recently, it has been observed that the
inhibition of AGT mRNA expression attenuates bleomycin-
induced lung fibrosis [15]. The regulation of cytokine produc-
tion in individuals has a major genetic component. The human
gene encoding AGT is located on chromosome 1q42.3 and a
large number of single-nucleotide polymorphisms (SNPs) have
been described. Among them, the SNP G-6A nucleotide
substitution at position -6 upstream from the initial transcrip-
tion start has been studied particularly. The A allele has been
associated in vitro with an increased expression of the AGT gene
and with higher AGT synthesis [16]. Given the proven
relationship between AGT and IPF, the present authors
hypothesised that changes in the expression of AGT gene may
be involved in the pathogenesis of the disease. Accordingly, the
current study investigated whether the SNP G-6A is associated
with the development and progression of IPF.
MATERIALS AND METHODS
Subjects
The control group was composed of 224 unrelated healthy
subjects (mean¡SD age 40¡13 yrs; 80 males and 144 females)
with no associated medical disease. White Caucasian subjects
from Spain were selected for the study in four different
hospitals (Hospital Clı´nico and Hospital Vall d’Hebron,
Barcelona; Hospital La Princesa, Madrid; and Hospital
Virgen del Rocio, Sevilla, Spain). Any subjects with diseases
related to potential tissue fibrosis were excluded from the
study. The representative nature of the control group for the
Spanish population has been previously demonstrated in
human leukocyte antigen genotyping studies [17]. The IPF
group was composed of 219 unrelated patients (age
67.3¡10 yrs; 136 males and 83 females). The diagnosis of IPF
was established according to the American Thoracic Society/
European Respiratory Society Consensus Statement [1].
Histological diagnosis was obtained in 89 (40.6%) out of the
219 patients. Pulmonary function tests were performed as
previously described and the reference values used were from
the present authors’ laboratory [18]. The alveolar–arterial
oxygen tension difference (PA–a,O2) was calculated according
to the standard formula, using the actual respiratory exchange
ratio [19]. Among the IPF patients, 181 were followed up for
33¡23 months; the following included the assessment of
clinical data and lung function. The main reason for subjects
discontinuing with the study was death. The Human Ethics
Committee at each participating hospital approved the study
and written informed consent was obtained from all subjects.
Identification of the polymorphism and primer sequences
Genomic DNA was extracted from peripheral leukocytes by a
salting out procedure [20]. PCR was used to assay G-6A alleles
and genotypes of each studied subject, using the following
primers: 59-forward-GTC GCT TCT GGC ATC TGT CC-39; 59-
reverse-CTT TTT CCT CCT AGC CCA CA-39. PCR cycling
conditions were as follows: 94uC for 5 min, followed by 35
cycles, each at 90uC for 30 s, 65uC for 30 s, and 72uC for 45 s,
and a final extension at 72uC for 7 min. The product was
digested with BstN I (NEB, Beverly, MA, USA) at 60uC for 2–
3 h, followed by electrophoresis on a 3% agarose gel, yielding
the following products: -6G: 173, 86 bp and -6A: 119, 86 and
55 bp.
Statistical analysis
Hardy–Weinberg Equilibrium held for each genotype within
the control group using the Chi-squared test with the
appropriate number of degrees of freedom [21]. Differences
in genotype and allele frequencies between case and control
groups were analysed with the Pearson Chi-squared test and
data were corrected by multiple comparisons. A logistic
regression model was fitted to the IPF data with SNP genotype
or allele effect of G-6A, with age and sex as covariates.
Differences in the mean values of continuous variables were
tested with an unpaired t-test or the Wilcoxon signed rank test.
The relationships between the progression of IPF (changes in
pulmonary function tests over time), the treatment, and the
type of genotype and allele were tested by ANCOVA,
adjusting the initial measure of the pulmonary function at
diagnosis. Results of disease progression were adjusted by age,
sex and smoking variables. Gauss–Markov conditions on
model residuals were examined and outliers were excluded
to ensure the model fitted. Data are expressed as mean¡SD. A
p-value of ,0.05 was considered statistically significant.
RESULTS
G-6A gene polymorphism in IPF patients and control
subjects
The genotype and allele frequencies of G-6A polymorphism of
AGT gene are summarised in table 1. There were no significant
differences in genotype and allele frequencies between the
control subjects and patients with IPF (genotypes: Chi-
squared51.25, p50.53; alleles: Chi-squared50.82, p50.36).
Both age and sex had significant association with a predis-
position for IPF; the risk of developing the disease was higher
in males (p,0.0087) and older patients (p,0.0001). Neither
SNP genotype nor allele of the -6ATG gene polymorphism was
significant in the development of IPF after adjusting for patient
age and sex. The reported genotype and allelic frequencies of
TABLE 1 G-6A genotype and allele frequencies
Control subjects IPF patients
Subjects n 224 219
Genotypes
AA 19.2 (43/224) 18.2 (40/219)
GA 53.6 (120/224) 52.5 (115/219)
GG 27.2 (61/224) 29.2 (64/219)
Allele
A 46 (206/448) 47 (207/438)
G 54 (242/448) 53 (231/438)
Data are presented as % (n/total n), unless otherwise stated. IPF: idiopathic
pulmonary fibrosis.
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G-6A gene polymorphisms in the control group did not differ
from those previously described in white Caucasian popula-
tions [22]. No deviations from Hardy–Weinberg Equilibrium
were seen in either male or female control groups. There was
no evidence for any interaction between sex and allele
frequencies (p50.48). There were no differences in allele
distribution across age groups in control and IPF populations.
Therefore, the G-6A polymorphism was not associated with
susceptibility to develop IPF.
IPF severity and disease progression related to genotype
and allele frequencies of G-6A gene polymorphism
The respiratory functional characteristics of the IPF patients are
summarised in table 2. Baseline pulmonary functional test
results did not significantly differ between G and A alleles.
Likewise, there was no significant correlation among G-6A
genotypes and baseline lung functional test values.
In total, 181 patients were monitored for 33¡23 months (range
3–114 months). Contact with the remaining 38 patients was
lost. Overall, patients showed deterioration in pulmonary
functional parameters (table 3). Changes in pulmonary func-
tion tests during the follow-up were expressed over time to
compare evolution between patients. The changes in pulmon-
ary function tests were divided by the whole follow-up period
in months. Decline in pulmonary functional values was not
significantly different between males and females (table 3). A
total of 130 monitored patients were treated with glucocorti-
coids, with or without azathioprine or cyclophosphamide and
N-acetylcysteine. The remaining 51 patients did not receive
medical treatment during the monitoring period. There were
no differences in the changes in pulmonary functional test
results between treated and untreated patients during the
evaluated months (table 4).
There was a strong association between the presence of the A
allele and the monthly increase in PA–a,O2 (0.83¡0.92 mmHg
(0.11¡0.12 kPa) versus 0.53¡0.7 mmHg (0.070¡0.093 kPa);
p50.001). Patients with the A allele who did not receive
treatment during follow-up presented higher PA–a,O2 than
patients with the A allele who were treated (p50.01).
Significant differences were observed in the PA–a,O2 changes
during the follow-up between patients with the AA genotype of
the AGT gene (0.36¡0.7 mmHg (0.048¡0.093 kPa) per month)
and those with GA genotype (0.12¡1 mmHg (0.016¡0.13 kPa)
per month) as well as in those with GG genotype
(0.2¡0.6 mmHg (0.027¡0.08 kPa) per month; p50.0015 and
p50.005, respectively; table 5). There were no differences
between the follow-up duration in patients with A and G alleles
(35.8¡27.7 months versus 31.7¡19.8 months, respectively). The
carriage of the G allele in IPF patients was associated with less
deterioration of forced vital capacity (FVC) but the difference
was not significant (p50.09). The decrease in FVC over time was
not significantly different between G-6A genotypes (table 5). No
differences in the diffusion capacity of the lung for carbon
monoxide (DL,CO) and DL,CO adjusted by alveolar volume (KCO)
were found between genotypes during follow-up (table 5).
However, a greater change in KCO was observed over time in
male patients carrying an A allele (p50.05).
DISCUSSION
The present study demonstrates, for the first time, the
relationship between the G-6A polymorphism of the AGT
gene and IPF disease progression. The results show that the
G-6A gene polymorphism does not confer susceptibility to IPF,
as no differences are seen in the distribution of genotypes and
allele frequencies between patients and healthy subjects.
However, the presence of the A allele and AA genotype at
the -6 position in the core promoter of the AGT gene is
associated with an increased deterioration in gas exchange and
pulmonary function in patients with IPF. This finding suggests
a potential use for the G-6A gene polymorphism as a
prognostic marker in IPF to predict poor outcome and to aid
selection of the appropriate therapeutic intervention.
Several studies have been undertaken in IPF patients in order
to find genetic links to shed more light on the disease’s
pathogenesis and suggest target pathways for therapy [10, 23].
The pathophysiology of IPF is likely to be determined by
multiple genetic factors that each contribute to disease
development [10, 23]. Following the evolving hypothesis,
which suggests that IPF is a consequence of impaired wound
TABLE 2 Baseline pulmonary function test findings in
patients with idiopathic pulmonary fibrosis
Absolute % pred
FVC L 2.37¡0.7 71.66¡17.24
FEV1 L 1.95¡0.5 78.51¡18.13
FEV1/FVC % pred 83.5¡0.05
TLC L 3.94¡1.1 71.91¡15
DL,CO mL?min-1?mmHg-1 13.37¡0.51 57.89¡1.78
KCO mL?min-1?mmHg-1?L-1 3.73¡0.1 79.86¡2.36
Pa,O2 mmHg 75.09¡0.14
PA–a,O2 mmHg 27.22¡1.12
Data are presented as mean¡SD. % pred: % predicted; FVC: forced vital capacity;
FEV1: forced expiratory volume in one second; TLC: total lung capacity; DL,CO:
diffusion capacity of the lung for carbon monoxide; KCO: ratio between DL,CO and
alveolar volume; Pa,O2: arterial oxygen tension; PA–a,O2: alveolar–arterial oxygen
tension difference. 1 mmHg50.133 kPa.
TABLE 3 Changes in pulmonary function tests in the
follow-up study
Values Males Females
Patients n 181 107 74
FVC -0.47¡1.2 -0.49¡1.3 -0.45¡0.87
DL,CO -0.72¡1.4 -0.78¡1.8 -0.70¡1.5
KCO -0.2¡0.9 -0.27¡0.8 -0.18¡1.1
PA–a,O2 mmHg 0.19¡0.9 0.32¡0.8 0.12¡0.6
Unless otherwise stated, data are presented as the mean¡SD percentage of
change in absolute values or difference in pressure (mmHg) with respect to
initial assessment, divided by the length of follow-up in months. FVC: forced
vital capacity; DL,CO: diffusion capacity of the lung for carbon monoxide; KCO:
ratio between DL,CO and alveolar volume; PA–a,O2: alveolar arterial oxygen
tension difference. 1 mmHg50.133 kPa.
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healing involving the epithelial/fibroblast pathway [2], many
candidate genes for growth factors, as well as other molecular
mediators implicated in this extensive process, have been
evaluated [24–28]. The first candidate genes to be analysed in
IPF patients were involved in inflammatory responses. Later
studies focused on surfactant protein gene variants, T-helper
cell type 1/type 2 cytokine polymorphisms and growth factors
involved in the epithelial/fibroblast altered pathway. Tumour
necrosis factor (TNF)-a, interleukin (IL)-1 receptor antagonist,
surfactant A and B protein and complement receptor 1 gene
polymorphisms have been associated with increased risk of
developing pulmonary fibrosis [24–28]. PANTELIDIS et al. [27]
have shown that there is a strong correlation between the
cocarriage of IL-6 and TNF-a receptor II genetic variants and
IPF [27]. The presence of TGF-b1 and IL-6 polymorphisms have
been linked with IPF progression due to their association with
lung function deterioration over time [25, 27].
ANG II is a growth factor that plays an important role in the
fibrogenic process of different organs. It is a crucial factor in
the pathogenesis of lung fibrosis due to its contribution to
abnormal wound healing [13]. In vitro and in vivo studies have
shown that ANG II induces epithelial cell apoptosis, increases
lung collagen deposition and enhances TGF-b1 synthesis [11,
13], whereas its inhibition or antagonism attenuates experi-
mental lung fibrogenesis [12]. It has been shown that alveolar
epithelial cell apoptosis induced by Fas ligand, TNF-a,
bleomycin or amiodarone requires ANG II generation, while
a blockade of ANG II production or receptor interaction can
block cell death [11–13]. ANG-converting enzyme (ACE), the
main enzyme involved in ANG II synthesis, is found at higher
levels in the bronchoalveolar lavage fluid of patients with
interstitial lung diseases and higher levels of ACE have been
observed in the fibrotic stage of sarcoidosis [29]. It has recently
been shown that ANG II and AGT are overexpressed in lungs
of IPF patients, with a strong linkage with alveolar apoptotic
epithelial cells and myofibroblasts [14]. Interestingly, the
treatment of IPF fibroblast cultures with the ANG II
antagonists decreases TGF-b1 synthesis and lung collagen
deposition [13].
The genetic variability of ANG II synthesis could lead to the
identification of subjects with a higher risk of ANG II effects.
The present authors investigated the G-6A polymorphism in
the core promoter region of the AGT gene, which is known to
be the main regulator of AGT expression and synthesis [16].
The G-6A polymorphism was found to influence disease
progression in IPF patients. The presence of the A allele and
AA genotype is strongly correlated with PA–a,O2 gradient
deterioration over time. It is well known that the rate of decline
in pulmonary function across the IPF population is not linear,
so the present findings are not able to evaluate acute
exacerbations or periods with no change over time in these
patients. Since A allele carriage and AA genotype have been
associated with higher AGT levels, it may well be that
increases in ANG peptides influence the evolution of the
disease. Previous work in liver fibrosis has described a positive
association between -6 AA gene variants and an advanced
grade of fibrosis, although genotype frequencies were not
different from those of the control population [22]. Studies of
ANG system gene polymorphisms in lung diseases have
revealed that there is an increase in the D allele of the ACE
gene in pulmonary fibrosis and in noninfectious pulmonary
dysfunction that leads to allogenic stem cell transplant [30, 31].
Therefore, these results, together with the present findings,
suggest that ANG system gene variants could be involved in
interstitial lung fibrotic diseases.
In conclusion, the results of the present study raise the
possibility that the G-6A polymorphism plays an important
role in gas exchange and lung function deterioration in patients
with idiopathic pulmonary fibrosis. The present study is the first
to link the genetic variations in angiotensinogen with disease
progression. Knowledge of this polymorphism may have a
predictive significance in patients with idiopathic pulmonary
fibrosis, and physicians may be able to use more aggressive
therapy in those patients with a high risk of disease progression.
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TABLE 4 Changes in pulmonary function test results in
treated and untreated patients with idiopathic
pulmonary fibrosis over time
Treated Untreated p-value
Patients n 130 51
FVC -0.52¡1.1 -0.44¡1.1 NS
DL,CO -0.78¡1.8 -0.83¡1.8 NS
KCO -0.04¡1.9 -0.18¡1.8 NS
PA–a,O2 mmHg 0.22¡0.95 0.2¡0.89 NS
Unless otherwise stated, data are presented as the mean¡SD percentage of
change in absolute values or difference in pressure (mmHg) with respect to
initial assessment, divided by the length of follow-up in months. FVC: forced
vital capacity; NS: not significant; DL,CO: diffusion capacity of the lung for carbon
monoxide; KCO: ratio between DL,CO and alveolar volume; PA–a,O2: alveolar
arterial oxygen tension difference. 1 mmHg50.133 kPa.
TABLE 5 Changes in pulmonary function tests between
G-6A genotypes during follow-up study
AA GA GG
Patients n 32 87 62
FVC -0.73¡1 -0.35¡1.3 -0.5¡1
DL,CO -0.7¡0.8 -0.8¡1.6 -0.6¡1.5
KCO -0.22¡0.6 -0.26¡1.2 -0.15¡0.8
PA–a,O2 mmHg 0.36¡0.7 0.12¡1
# 0.2¡0.6"
Unless otherwise stated, data are presented as the mean¡SD percentage of
change in absolute values or a difference in pressure (mmHg) with respect to
initial assessment, divided by the follow-up in months. FVC: forced vital
capacity; DL,CO: diffusion capacity of the lung for carbon monoxide; KCO: ratio
between DL,CO and alveolar volume; PA–a,O2: alveolar arterial oxygen tension
difference. 1 mmHg50.133 kPa. #: p50.0015; ": p50.005.
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